Physician profile
Abiola O Amure
NPI 1427534205
$14,572.72
in general payments reported to CMS, 2019-2025
63 companies · $61.81 in 2025
The $61.81 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,896 · 2022: $6,434 · 2023: $3,901 · 2024: $280 · 2025: $61.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,901.04 | 2021-2025 | |
| Livanova USA, INC. | $1,743.90 | 2022 | |
| Biogen, INC. | $1,081.68 | 2021-2023 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $566.56 | 2021-2023 | |
| Genzyme Corporation | $448.03 | 2021-2023 | |
| Emd Serono, INC. | $441.80 | 2021-2023 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $440.23 | 2021 | |
| Amgen INC. | $435.24 | 2021-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company Ltd. | $430.35 | 2022 | |
| Ucb, INC. | $403.16 | 2021-2023 | Briviact |
| Genentech USA, INC. | $384.81 | 2021-2023 | Ocrevus, Enspryng |
| Lilly USA, LLC | $369.51 | 2021-2023 | Emgality, Amyvid, Reyvow |
| Upsher-Smith Laboratories LLC | $353.18 | 2021-2023 | |
| Lundbeck LLC | $352.21 | 2021-2023 | Vyepti, Rexulti |
| Avanir Pharmaceuticals, INC. | $315.85 | 2021-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abiola Amure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.